Anaplastic supratentorial cortical ependymoma presenting as a butterfly lesion

David W. K. Ng, Nicolas K. K. King, Aaron S. C. Foo, Yih-Yian Sitoh1, Hwei Yee Lee2, Wai Hoe Ng

Departments of Neurosurgery, 1Neuroradiology, 2Pathology, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore

E-mail: David W. K. Ng - david.ng@mohh.com.sg; *Nicolas K. K. King - Nicolas_kon@nni.com.sg; Aaron S. C. Foo - aaron.foo@mohh.com.sg; Yih-Yian Sitoh - Yih_Yian_Sitoh@nni.com.sg; Hwei Yee Lee - Hwei_Yee_Lee@ttsh.com.sg; Wai Hoe Ng - Wai_Hoe_Ng@nni.com.sg

*Corresponding author

Received: 16 May 12 Accepted: 07 August 12 Published: 13 September 12

INTRODUCTION

Ependymomas are tumors arising from the cells lining the ventricular system and the central canal of the spinal cord. In adults, ependymomas are uncommon, have a propensity to occur supratentorially and are associated with a higher incidence of anaplasity.[18] Supratentorial ependymomas (STE) can be further divided into intraventricular and extraventricular types [Table 1]. Intraventricular ependymomas can be in either the third ventricle or lateral ventricles. Extraventricular ependymomas arise distant to the ventricles within the cerebral parenchyma and can even be purely cortical, arising purely within the cerebral cortex. The origin of the extraventricular STE is thought to be from fetal ependymal cell rests located in the periventricular region or at the angles of the ventricles.[20] Pure cortical ependymomas are the rarest, and we present, to our knowledge, a previously unreported case of an anaplastic ependymoma presenting as a butterfly lesion crossing the midline.

CASE REPORT

A 51-year-old Chinese female presented with the incidental finding of a large heterogeneously enhancing mass in the frontal lobes after a computer tomography (CT) scan for minor head injury following a fall [Figure 1]. Her past medical history included only adenomyosis and endometrial polyps. No neurological abnormalities were observed. Magnetic resonance imaging (MRI) revealed a $76 \times 70 \times 54$ mm mass in both frontal lobes with extension across the midline that was hypointense on T1-weighted, hyperintense on T2-weighted images, and...
demonstrated avid postgadolinium contrast enhancement [Figure 2]. The lesion showed foci of calcification and peripheral cystic components, with mild perilesional edema and significant mass effect. The corpus callosum was displaced posteriorly. Inferiorly, the lesion extended up to the olfactory bulb.

The patient underwent gross total resection (GTR) of the tumor. Intraoperatively the tumor was not found to breach ventricles and the tumor was deemed to be entirely extraventricular. Intraoperative frozen section suggested the diagnosis of a high grade glioma. Histology showed a well demarcated cellular tumor [Figure 3] with prominent perivascular pseudo-rosettes and very occasional true (ependymal) rosettes. The tumor cells showed enlarged, hyperchromatic, pleomorphic nuclei, a granular ‘salt and pepper’ chromatin pattern, and fibrillary cytoplasm. Mitotic figures, including atypical forms were readily identified. There were areas of palisading necrosis and microvascular proliferation. The Ki-67 proliferative index was about 20%. These features were diagnostic of an anaplastic ependymoma (WHO grade III).

MRI taken on postoperative day 1 [Figure 4] showed no evidence of residual tumor. The patient’s postoperative recovery was uneventful. Cerebrospinal fluid (CSF) studies were negative for malignant cells and no drop metastases were detected on neuroaxis MRI. The patient underwent adjuvant intensity-modulated radiation therapy of 60 Grays in 30 fractions to a region encompassing the tumor bed and a 2 cm margin around it over a period of 2 months. At follow up, the patient developed local recurrence in the frontal lobes within 2 months of completing radiotherapy. At 8 months postsurgery, progression of disease locally had caused her to become increasingly drowsy and by then she was wheelchair bound.

DISCUSSION

The term ‘butterfly lesion’ describes lesions that extend cross the midline, often via involvement of the corpus callosum. Lesions are typically aggressively infiltrative tumors such as glioblastoma multiforme (GBM) and B-cell lymphoma, and, given that the corpus callosum comprises primarily of myelinated axons, demyelinating disease such as multiple sclerosis.[5,6] In an immunocompromised patient, primary central nervous system (PCNS) lymphoma, progressive multifocal leukoencephalopathy, and rarely, toxoplasmosis have been reported.[5,7,8] In our patient the corpus callosum was found to have been displaced posteriorly rather than infiltrated, a feature that helped to differentiate her tumor from an infiltrative process. As cortical STEs are rare and have not been reported to present as butterfly lesions, they were not considered in our pre-operative differential diagnosis.

STE s are usually large (≥4 cm) and cystic with their location classified as shown in Table 1. On CT they demonstrate moderate to intense contrast enhancement with homogeneous or ring-enhancement patterns. On MRI, they appear hypointense on T1-weighted and hyperintense on T2-weighted imaging, respectively. Peritumoral edema and hydrocephalus may be present and about one-third of tumors may harbor calcification.[5,29] Extraventricular tumors tended to present with seizures, focal neurological deficits, and behavioral disturbances.
while intraventricular lesions present with hydrocephalus and raised intracranial pressure.\textsuperscript{[15,30,31]}

Although the clinical features in this case were highly suggestive of a GBM, this was later disproved by the classic histopathological features of an anaplastic ependymoma. There are also no known cases of GBM with ependymal differentiation reported in the literature.

**Table 1: Classification of adult supratentorial ependymomas by tumor location**

| Classification of STE          | Definition            | No. of cases | Studies |
|-------------------------------|-----------------------|--------------|---------|
| Intraventricular              | Arising from ventricles | a. 1         | a. Danyemez (1999)\textsuperscript{[15]} |
|                               |                       | b. 1         | b. Hayashi (2000)\textsuperscript{[9]} |
|                               |                       | c. 1         | c. Ragel (2005)\textsuperscript{[22]} |
|                               |                       | d. 24        | d. Metellus (2008)\textsuperscript{[15]} |
| Extraventricular              | Parenchymal/Subcortical | a. 2 (thalamic) 23 (parenchymal) | a. Molina (1999)\textsuperscript{[17]} |
|                               |                       | b. 22        | b. Metellus (2008)\textsuperscript{[15]} |
| Pure Cortical                 |                       | a. 1         | a. Saito (1999)\textsuperscript{[26]} |
|                               |                       | b. 2         | b. Roncaroli (2005)\textsuperscript{[23]} |
|                               |                       | c. 3         | c. Niazi (2008)\textsuperscript{[19]} |

**Table 2: Case series reporting on outcome in adult with supratentorial ependymomas following treatment**

| Study            | N  | WHO Grade (%) | Surgery GTR (%) | Adjuvant RT (%) | Chemo | Outcome |
|------------------|----|---------------|-----------------|-----------------|-------|---------|
| Saito (1999)\textsuperscript{[26]} | 1  | II (100)      | 100             | 100              | None  | NED at 14 months |
| Molina (1999)\textsuperscript{[17]} | 25 | III (100)     | 96              | 80              | 12%   | 5-year OS: 16.0% |
| Roncaroli (2005)\textsuperscript{[23]} | 2  | II (100)      | 100             | 50              | None  | 5-year OS: 100% |
| Metellus (2007)\textsuperscript{[14]} | 46 | II (46) III (54) | 50             | 48              | None  | 5-year OS: 63% ± 9% |
| Niazi (2008)\textsuperscript{[19]} | 3  | II (33) III (67) | 100             | 67              | None  | 1 death after 14 months, and NED at 29 months and at 42 months |
| Metellus (2010)\textsuperscript{[16]} | 22 | II (100)      | 55              | 32              | None  | 5-year OS: 75% ± 11% |

GTR: gross total resection, NED: No evidence of disease, OS: overall-survival, RT: radiotherapy

Several prognostic factors have been identified with regard to survival outcome and tumor recurrence. Compared with infratentorial or spinal ependymomas, patients with STE tend to have poorer overall survival (OS) and progression-
free survival (PFS) in patients. Other predictors of poor prognosis include older age, presence of microvascular proliferation, presence of necrosis, number of mitoses, degree of hypercellularity, and greater Ki-67/MI.B-1 proliferation index. Extent of tumor resection was a positive predictor of OS and PFS, and a lack of consensus in establishing the dissemination and metastasis. There is controversy about the prognostic value of the current histological grading system, and a consensus in establishing the criteria for classifying tumors according to the degree of anaplasticity. However, overall histological grade and incompleteness of resection have been identified as significant predictors of tumor recurrence.

Maximal safe resection with adjuvant radiotherapy (RT) is the current mainstay of treatment. There has been interest in identifying patients in whom RT can be avoided after surgery for STE. The treatment of STE as the cortical lesions have a negligible risk of drop metastases and leptomeningeal seeding due to their distance from CSF pathways. The overall outcome after surgery for STE is summarized in 2.

Our case is a unique case of an adult anaplastic supratentorial cortical ependymoma presenting as a butterfly lesion. This particular diagnosis should be considered in the differential diagnosis of such butterfly lesions in an adult [Table 2].

REFERENCES

1. Amiran ES, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of survival among older adults with ependymoma. J Neuro Oncol 2012;107:183-9.
2. Armington WG, Osborn AG, Cuberley DA, Harnsberger HR, Boyer R, Naidich TP, et al. Supratentorial ependymoma: CT appearance. Radiology 1985;157:367-72.
3. Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR. Adult ependymal tumors: Prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol 2010;12:862-70.
4. Awaad YM, Allen JC, Miller DC, Schneider SJ, Wisoff J, Epstein FJ. Deferring adjuvant therapy for totally resected intracranial ependymoma. Pediatr Neurol 1996;14:216-9.
5. Bourkeas EC, Varakia K, Burns D, Christoforidis GA, Baujan M, Slone HW, et al. Lesions of the corpus callosum: MR imaging and differential considerations in adults and children. AJR Am J Roentgenol 2002;179:251-7.
6. Bowers RS, Burris TM, Giannini C, Erickson BJ, Meyer FB, Pirko, et al. Teaching neuroradiograms: Demyelinating disease mimicking butterfly high-grade glioma. Neurology 2010;75:e-5.
7. Chaudhari VY, Yim CM, Hathout H, Lai A, Donovan SM. Atypical imaging appearance of toxoplasmosis in an HIV patient as a butterfly lesion. J Magn Reson Imaging 2009;30:873-5.
8. Daneyemmez M, Can C, Izc Y, Beduk A. Timucaynak E. The tanyctopic ependymoma of the lateral ventricle: Case report. Minim Invasive Neurosurg 1999;42:201-3.
9. Hayashi S, Kameyama S, Fukuda M, Takahashi H. Gangliogioma with a tanycytic ependymoma as the glial component. Acta Neuropathol 2000;99:310-6.
10. Hukin J, Epstein F, Lezon D, Allen J. Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 1998;29:40-5.
11. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N. Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg 2005;103:31-7.
12. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: An analysis of 258 patients. Cancer 2004;100:1220-7.
13. Mansur DB, Perry A, Rajaram V, Michalski JM, Park TS, Leonard JR, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 2005;61:387-91.
14. Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Gouvernet J, et al. Multicentric French study on adult intracranial ependymomas: Prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007;130(Pt 5):1338-49.
15. Metellus P, Figarella-Branger D, Guyotat J, Barrie M, Giorgi R, Jouvet A, et al. Supratentorial ependymomas: Prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer 2008;113:175-85.
16. Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R, et al. Adult intracranial WHO grade II ependymomas: Long-term outcome and prognostic factor analysis in a series of 114 patients. Neurol Oncol 2010;12:976-84.
17. Molina OM, Colina JL, Lizardo GD, Mendez OE, Cardozo D, Vesalquez HS, et al. Extraventricular cerebral anaplastic ependymomas. Surg Neurol 1999;51:630-5.
18. Mork A, Loken A. Ependymoma. Cancer 1977;40:907-15.
19. Niazi TN, Jensen EM, Jensen RL. WHO Grade II and III supratentorial hemispheric ependymomas in adults: Case series and review of treatment options. J Neurooncol 2009;91:323-8.
20. Oya N, Shibamoto Y, Nagata Y, Negoro Y, Hiraoka M. Postoperative radiotherapy for intracranial ependymoma: Analysis of prognostic factors and patterns of failure. J Neurosurg 2002;56:87-94.
21. Papadopoulos DP, Giri S, Evans RG. Prognostic factors and management of intracranial ependymomas. Anticancer Res 1990;10:689-92.
22. Paulino AC. The local field in infratentorial ependymoma: Does the entire posterior fossa need to be treated? Int J Radiat Oncol Biol Phys 2001;49:757-61.
23. Ragel BT, Townsend JJ, Arthur AS, Couldwell WT. Intraventricular tanyctic ependymoma: Case report and review of the literature. J Neurooncol 2005;71:189-93.
24. Reni M, Brandes AA, Vavassori V, Cavallo G, Casagrande F, Vastola F, et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004;100:1221-9.
25. Roncaroli F, Consales A, Fioravanti A, Cencacchi G. Supratentorial cortical ependymoma: Report of three cases. Neurosurgery 2005;57:E192.
26. Saito T, Oki S, Mikami T, Kawamoto Y, Yamaguchi S, Kuwamoto K, et al. Supratentorial eptopic ependymoma: A case report. No Shinkei Geka 1999;27:1139-44.
27. Schwartz TH, Kim S, Glick RS, Bagiella E, Balmaceda C, Fetell MR, et al. Supratentorial ependymoma in adult patients. Neurosurgery 1999;44:721-31.
28. Shanghato H, Rushing EJ, Mena H, Olsen C, Sandberg GD. Supratentorial extraventricular ependymal neoplasms: A clinicopathologic study of 32 patients. Cancer 2005;103:658-605.
29. Spoto GP, Press GA, Hessellink JR, Solomon M. Intracranial ependymoma and subependymoma: MR manifestations. AJNR Am J Neuroradiol 1990;11:83-91.
30. Van Gompel JJ, Koeller KK, Meyer FB, Marsh WR, Burger PC, Roncaroli F, et al. Cortical ependymoma: An unusual epileptogenic lesion. J Neurosurg 2011;114:1187-94.
31. Yadav YR, Neha, Chandralak SK. Pure cortical supratentorial extraventricular ependymoma. Neurol India 2009;57:213-5.